{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001294","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.141020+00:00","generated_at":"2026-06-11T21:20:53.197012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward","bullets":["Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.","GAAP net income $97.0M (−11.3%), diluted EPS $1.89; non-GAAP EPS $2.69 (−2.9%).","RMS segment revenue $209.9M (+12.6%, organic +13.9%) driven by China model shipments; Manufacturing segment revenue $186.5M (−4.2%).","FY 2023 guidance narrowed: organic revenue growth 5.5%–7.5% (prior 5.0%–7.5%); non-GAAP EPS $10.30–$10.90 (prior $9.90–$10.90).","CEO cites cautious biopharma spending but confidence in differentiated scientific breadth and DSA backlog."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001294","json":"https://secwatch.observer/filing/0001157523-23-001294.json","markdown":"https://secwatch.observer/filing/0001157523-23-001294.md","text":"https://secwatch.observer/filing/0001157523-23-001294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/0001157523-23-001294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/a53513759.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:20:53.197012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23d2817a1e3793b5a988f852a86b560527dbd10f","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the second quarter of 2023 results: revenue $1.06 billion, EPS $1.89. Guidance reaffirmed.","evidence_excerpt":"EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53513759ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--August 9,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323001294/0001157523-23-001294-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$1.06 billion"},{"label":"EPS","value":"$1.89"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}